Autogenous Vaccines Market

Autogenous Vaccines Market Outlook (2023-2033)

Worldwide revenue from the autogenous vaccines market stands at US$ 129.6 Mn in 2022, with the global market estimated to surge ahead at a CAGR of 5.4% to reach a valuation of US$ 231.6 Mn by the end of 2033.

As assessed by Persistence Market Research, bacterial strain segment is expected to hold a largest market value of US$ 92.7 Mn by 2023. Overall, autogenous vaccines market sales account for approximately 1.3% revenue share in the global veterinary vaccines market, which was valued at around US$ 9.9 Bn at the end of 2022.

Sales Analysis of the Global Autogenous Vaccines Market from 2015 to 2022 Vs Market Outlook for 2023 to 2033

The global market for autogenous vaccines recorded a historic CAGR of 4.7% in the last 7 years from 2015 to 2022.

The main factors driving the market for autogenous vaccines are the rise in zoonotic disease incidence and the prevalence of rare infectious diseases in livestock and companion animals. Increasing government initiatives to prevent viral disease and progress in the biomedical sciences have created a market for autogenous vaccines. The market is anticipated to develop as a result of factors such as rising pet adoption rates, improved animal safety education, and a decline in the requirement for antibiotics.

Antimicrobial use in animals typically results in the development of resistant microorganisms that can be passed directly from animal to human or through the food chain. Veterinarians and pig farmers are looking for strategies to safeguard their livestock from infectious diseases since they are aware of the potential risks associated with the use of antibiotics in animals. One of the steps being taken to enhance health and reduce economic losses brought on by infectious diseases is the use of autogenous vaccines. Additionally, it is better to produce herd-specific autogenous vaccines since they offer protection against both viruses and bacteria. These advantages of autogenous vaccines offer lucrative potential for market expansion.

Periodic animal inspections and vaccinations are necessary to guarantee that livestock is of high quality, which is anticipated to contribute to the rise of the need for autogenous vaccines throughout the forecast period. It is anticipated that increasing efforts by different governments worldwide to secure food security will sustainably increase demand for autogenous vaccines, particularly for swine.

The global market is thus likely to show high growth over the coming years at a CAGR of 5.4% and reach a global market size of US$ 231.6 Mn by 2033.

What Factors Will Drive the Autogenous Vaccines Market to Grow Over Forecast Period?

“Managing Livestock and Management of Diseases to Create High Demands for Autogenous Vaccines”

Animal husbandry activities should be strengthened and the usage of antibiotics used to treat sick animals or herds needs to be reduced in light of the rising public interest in the health and welfare of animals intended for human consumption. For instance, decreased use of antibiotics in developed nations like Germany has significantly reduced the loss of the majority of animals. However, due to the limited availability of veterinary medicines, managing vaccination is a significant difficulty for some species, such as turkeys, which are regarded of as minor species. As a result, accessible products are used to treat affected animals.

• Additionally, there aren't many licensed vaccinations and medicines available to treat sick and diseased flocks or to boost the innate immune system's defenses against infections. The production of autogenous vaccines for rare or minor species serves as an efficient management approach to enhance animal health and reduce animal mortality from infectious diseases. Consequently, this strategy will result in greater adoption of autogenous vaccines.

“Creation of Customized Autogenous Vaccines to Boost the Market”

Reoviruses are constantly changing and evolving, and there are numerous serotypes that are harmful to poultry health and performance. As a result, many manufacturers are striving to create custom autogenous poultry reovirus vaccines. These vaccines include farm-specific serotypes to guarantee a close match for the field's constantly shifting environment. The most effective way for poultry producers to address continuing antigenic changes in the field is with autologous vaccinations. For instance, Phibro Animal Health Company added solutions for antigen combinations to its existing range of autogenous vaccines in April 2020. These advanced and customized vaccines will assist poultry farmers in protecting their animals against a variety of infectious diseases.

“Enhancing Direct Customer Interactions to Result in Increased Adoption of Veterinary Products”

Manufacturers of animal healthcare products, particularly those for poultry, rely heavily on their direct sales staff to connect with customers more effectively. Companies use this strategy to promote awareness as well as disease management, treatment protocol, and training & assistance.

• In this regard, Zoetis stated that the company offer its products directly to a wide range of end users, including large retail pharmacies, cattle and dairy farmers, poultry farmers, veterinarians, and third-party veterinary distributors.

To improve their relationship and establish trust, manufacturers in the market for autogenous vaccines make extensive attempts to develop direct customer relations. Many local manufacturers follow similar processes to improve the effectiveness of their products for specific customers as well as for better profitability.

Is there Any Impact on the Growth of the Global Autogenous Vaccines Market?

“Gaps in Epidemiological Knowledge of Certain Virulent Veterinary Diseases”

Due to differences in disease patterns for endemic nations, there is a significant limited knowledge regarding the epidemiology pattern of veterinary diseases. A common example is Newcastle Disease in poultry, for which there is a major economic loss in the global poultry trade due to the absence of epidemiological knowledge. Due to isolates that are dispersed globally and rapidly mutate, the virulent Newcastle disease virus (vNDV) is emerging simultaneously at many places. This causes significant knowledge gaps regarding the emergence of various vNDV genotypes. This hinders the development and manufacture of vaccines to stop the disease's spread. Repeated viral infections in domestic and wild birds enable the development of a virus reservoir. The expansion of the global market for autogenous vaccines is anticipated to be significantly hampered by this aspect.

“Stringent Regulatory Framework for Vaccine Production and Export”

Autogenous biologics should be developed in a facility that has a license since they are specialized vaccinations made up of antigens. Additionally, laws governing the development of autogenous vaccines differ from nation to nation. Every nation has its own regulations and license requirements for vaccine manufacture. While some nations have uniform laws for the use of autogenous vaccinations, others have none at all. Countries must establish their rules in order for autogenous vaccines to be distributed properly.

As a result, the market's expansion is probably going to be constrained by strict restrictions and protracted license application processes.

Country-wise Insights

Why is the U.S. Autogenous Vaccines Market Booming?

“Government Support and Well Developed Vet Care System”

The U.S. is expected to hold around 34.5% market share in the global autogenous vaccines market at the end of 2023.

Through government initiatives and programs, farmers are made more aware of livestock diseases and their preventive measures. For instance, the USDA's Animal and Plant Health Inspection Service (APHIS), the USDA's Animal Research Service (ARS), manufacturers, and public health officials all work together to conduct a surveillance program with the goal of advancing scientific study that will address issues pertaining to veterinary and public health. Support researchers and the animal health sector to develop and improve suitable diagnostic reagents, specialized diagnostic assays for influenza, effective vaccines, and response plans is one of this program's main goals. Such campaigns to raise awareness about animal health are anticipated to speed up R&D, resulting in the release of customized vaccines in the U.S.

Will the Germany Be a Lucrative Market for the Manufacturers?

“Better Regulatory Scenarios for Veterinary Products”

With an 8.9% market share, Germany will hold a fair amount of share in global market at the end of 2023.

Veterinarians and pet owners need autogenous vaccines, which are frequently utilised in Germany, where such products have been used for the longest time. Germany is therefore dominating the European market. Germany currently holds the top spot in the regional market because of a variety of factors, including improved product accessibility across the country, favorable regulatory conditions, growing awareness of animal health among poultry farmers and livestock breeders, and increased public funding for research and development of new vaccines.

How is Japan Emerging as a Prominent Market for Autogenous Vaccines?

“Growing Livestock Industry”

Japan is estimated to hold market share of less than 1% of the global autogenous vaccines market in 2023.

Autogenous vaccine manufacturers are working very hard to engage with end users directly in the country. This strategy is being used by companies to increase awareness of animal health, particularly among livestock producers because they deal with a large number of animals. The demand for vaccines from livestock companies in Japan is also anticipated to rise as a result of increased financing and support for international veterinary disease eradication efforts and the rising popularity of animal health insurance.

Category-wise Insights

Which Product Segment is Driving Growth of the Global Autogenous Vaccines Market?

“Major Advantages of Bacterial Strains in Vaccines”

Bacterial Strain segment is expected to hold highest share within the product segment with a market value of US$ 92.7 Mn by 2023.

Live bacterial vaccines provide several benefits, such as the ability to replicate a real infection, built-in adjuvant qualities, and better oral administration options. These reasons have led to a growing use of bacterial strains in the creation of specialized autogenous vaccines.

Which End User is Expected to Emerge as a Market Leader in the Future?

“Increasing Number of Livestock Farming Worldwide”

Livestock farming companies segment is expected to hold the larger share of about 47.9% by the end of 2023.

Worldwide, the livestock sector is very active. It is transforming in emerging nations as a result of the rapidly rising demand for animal products. The consumption for livestock products has been primarily driven by increases in human population, income, and urbanization.

Competition Landscape

There are both worldwide and regional market players in the autogenous vaccines industry. Leading companies emphasize inorganic expansions as one of their primary growth strategies in order to maintain market competitiveness. Additionally, industry participants are working to increase their local and international reach through mergers and acquisitions.

Key instances include:

• In Jan 2020, Innoject Pro was a newly developed subcutaneous chick vaccination technology that was unveiled by Merck Animal Health, a division of Merck & Co., Inc., Kenilworth, New Jersey, USA, and Automazioni VX Inc.
• In Sep 2020, at its French facility, Ceva Santé Animale tripled its ability to produce bacterial autogenous vaccines, especially for pigs and poultry.

Autogenous Vaccines Industry Report Scope

Key Segments Covered in Autogenous Vaccines Industry Research

Product:

• Bacterial Strain
• Virus Strain

End User:

• Veterinary Research Institutes
• Livestock Farming Companies
• Veterinary Clinics and Hospitals

Region:

• North America
• Latin America
• Europe
• South Asia
• East Asia
• Oceania
• Middle East & Africa

To know more about delivery timeline for this report Contact Sales